TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today reported its financial results for the three and nine-month period ended September 30, 2016. Unless otherwise noted, all amounts are in U.S. dollars.
“During the quarter, Aytu Bioscience began commercializing NATESTO® in the U.S. and the demand for our product has been extremely encouraging and on a path to surpass previous highs. We are equally excited by the early response to the Canadian launch of NATESTO™ and look forward to sharing our successes in the coming months,” said Tom Rossi, President and Chief Executive Officer of Acerus.
